Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 14, 2014; 20(34): 11985-11990
Published online Sep 14, 2014. doi: 10.3748/wjg.v20.i34.11985
Published online Sep 14, 2014. doi: 10.3748/wjg.v20.i34.11985
Propofol sedation during endoscopic treatment for early gastric cancer compared to midazolam
Shinsuke Kiriyama, Hiroshi Naitoh, Department of Surgery, Gunma Chuo General Hospital, Maebashi, Gunma 371-0025, Japan
Hiroyuki Kuwano, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma 371-0025, Japan
Author contributions: Kiriyama S conceived the study and coordinated literature data; Kiriyama S, Naitoh H and Kuwano H drafted the manuscript.
Correspondence to: Shinsuke Kiriyama, MD, PhD, Department of Surgery, Gunma Chuo General Hospital, Maebashi, 1-7-13, Koun-cho, Mebashi, Gunma 371-0025, Japan. drkiriyama@yahoo.co.jp
Telephone: +81-27-2218165 Fax: +81-27-2241415
Received: October 25, 2013
Revised: February 25, 2014
Accepted: May 28, 2014
Published online: September 14, 2014
Revised: February 25, 2014
Accepted: May 28, 2014
Published online: September 14, 2014
Core Tip
Core tip: According to the literature, endoscopic submucosal dissection (ESD) has been proposed as the gold standard in the treatment of early gastric cancer. However, ESD requires safe sedation management. This review covers safe sedation using propofol and other sedative drugs in the context of the available literature. Moreover, understanding safe sedation could be important in managing perioperative patients with gastric ESD. To this end, we suggest that sedation using propofol is safe and results in patient satisfaction after endoscopic gastric treatment for ESD.